Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV ISIN · CA09076M2004 LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2024-08-16 Declaration of Voting R…
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a press release announcing the results of the Annual General Meeting (AGM) of shareholders held on August 15, 2024. It details shareholder approvals including election of directors and appointment of auditors, which are typical contents of AGM results announcements. The document also includes a correction to a previous financing announcement but does not contain detailed financial statements or comprehensive financial performance data. The length is 7440 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is the full Annual Report or any other detailed financial report. Therefore, the document fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes from the AGM.
2024-08-16 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 100% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about a securities distribution, including issuer details, distribution dates, types of securities distributed, purchaser information, compensation related to the distribution, and regulatory references to Canadian securities laws. This form is a regulatory filing used to report exempt distributions of securities, typically filed with Canadian securities regulators. It is not an annual report, earnings release, or any other financial report but a specific regulatory disclosure about securities distribution. The document is comprehensive and contains substantive data about the distribution event, fitting the category of a regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-08-11 English
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'FORM 51-102F3 MATERIAL CHANGE REPORT' and details a material change involving the closing of a tranche of a private placement and issuance of shares. It includes specifics about the transaction, insider participation, regulatory exemptions, and securities law compliance. The content focuses on a financing event and capital structure update rather than a full financial report or earnings release. The detailed description of the private placement and issuance of shares aligns with a Capital/Financing Update. The document length is about 5,286 characters, which is sufficient to contain substantive information rather than just an announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-08-11 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'FORM 51-102F3 MATERIAL CHANGE REPORT' and details a material change involving the closing of a tranche of a private placement and issuance of shares. It includes specifics about the transaction, insider participation, regulatory exemptions, and securities law compliance. The content focuses on a financing event and capital structure update rather than a full financial report or earnings release. The form and content align with a Capital/Financing Update filing rather than other categories like Annual Report or Earnings Release. The document length is over 5,000 characters and contains substantive details about the financing transaction, confirming it is not merely an announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-08-11 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings
2024-08-09 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of the second tranche of a private placement financing by BioVaxys Technology Corp. It details the issuance of shares and warrants, the use of proceeds, and related terms. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The content focuses on capital raising activities and financing updates. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is 7780 characters, which is sufficient for a detailed announcement but does not contain financial report data. Hence, the classification is CAP with high confidence.
2024-08-03 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.